New BRAF inhibiting cancer drug depicts promise in early patient trial
Category: #health  By Pankaj Singh  Date: 2020-10-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

New BRAF inhibiting cancer drug depicts promise in early patient trial

A novel drug against cancers with a transmuted BRAF gene has reportedly shown promise in a preliminary patient trial exhibited at the 32nd EORTC-NCI-AACR (virtual) Symposium on Molecular Targets and Cancer Therapeutics. Results of the first and second phase of the trial were reportedly demonstrated by Dr Filip Janku, Center Medical Director, Clinical and Translational Research Center, University of Texas.

Dr Janku stated that the existing BRAF inhibitors do not go for all patients having BRAF mutated cancers, given that in some cases, the cancer develops resistance even though these drugs appear to work in the beginning. The first generation BRAF inhibitors can also lead to skin cancers and unpleasant skin lesions in some patients and, therefore, the next generation BRAF inhibitor given to patients over this trial was designed for avoiding such issues.

Outcomes of the study indicate that the combination of drugs tested is comparatively safe and might be effective in case of some patients, stated Dr Janku.

While the BRAF gene plays a prominent role in directing the growth and formation of new cells, it is also cited to mutate or go wrong in multiple types of cancer, comprising skin, bowel, and brain cancer categories. The new drug, PLX8394, has been reportedly designed for avoiding cancer resistance and working against cancers having a broad range of BRAF mutations.

According to the Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, William Sellers, acknowledging which genes go adrift in cancer and the way they are mutated is a vital step towards the development of treatments that are targeted to give an effective performance in individual patients. Sellers has also stated that BRAF is mutated in smaller fragments of colorectal and lung cancer and covers almost half of melanoma patients, which makes it a significant therapeutic target while emphasizing on the clinical benefit of BRAF inhibitors in such patients.

 

Source Credit: https://www.eurekalert.org/pub_releases/2020-10/eofr-ngb102320.php



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...

Collier’s Medical to offer HealthySole UVC units for infection control
Collier’s Medical to offer HealthySole UVC units for infection control
By Pankaj Singh

Collier’s Medical Equipment, a leading distributor of technologically-advanced medical equipment, has reportedly inked an agreement with HealthySole. This agreement has been geared towards the delivery of Healthy...

Western Union to offer money transfer services at Walmart U.S. stores
Western Union to offer money transfer services at Walmart U.S. stores
By Pankaj Singh

Walmart, an American retail chain, and Western Union, a financial service company, have recently announced a new collaboration deal. The agreement will allow the money transfer services of Western Union to be deployed ...